title: [Expressions of CD117 and CD11b in patients with APL at diagnosis and post-treatment].
abstract: The aim of this study was to evaluate the value of CD117/CD11b phenotypic analysis to diagnosis and prognosis of acute promyelocytic leukemia (APL). Three- or four-color flow cytometry with a series of 22 monoclonal antibodies and CD45/Side Scatter (SSC) gating strategy were used to identify immunophenotypic characteristics of APL as compared to CML in chronic phase (CML-CP). PML/RAR alpha fusion gene was detected by using reverse-transcription polymerase chain reaction (RT-PCR) technique. The results showed that MPO, CD13 and CD33 were almost expressed in all patients with APL and CML-CP whereas HLA-DR and CD34, the hematopoietic progenitor cell markers, were rarely expressed. The positive rate of CD15 in APL was significantly lower than those in CML-CP (P < 0.01). CD117 was positive in 78.3% of the APL cases and in none of the cases of CML-CP. On the other hand, CD11b was almost positive in all cases of CML-CP, but only 16.9% of the APL cases were found positive for this antigen. The CD117+ CD11b- phenotype was present in 72.3% of APL cases while none of cases with CML-CP with this phenotype. Almost all of the cases with CML-CP had the phenotype of CD117- CD11b+. CD117- CD11b+ phenotype was detected in all patients recovering from APL with CD117+ CD11b- phenotype at diagnosis and after treatment with all-trans-retinoic acid (ARTA) for 2 months. PML/RAR alpha fusion gene was positive in 80.6% (25/31) of the APL cases, of which, 64% of the cases belonged to the type L while only 36% of the cases were showed type S for this fusion gene. The positive rates of CD117 were 87.5%, 44.4% and 33.3% in type L group, S group and negative group respectively. It is concluded that analysis of both CD117 and CD11b phenotype may be helpful to the diagnosis, therapy and prognosis of APL in children and adults and to differentiation of APL from recovering benign myeloid proliferation.
authors.affiliation: Department of Hematology and Oncology, Children Hospital, Zhejiang University Medical College, Hangzhou 310003, China. hoqshen@126.com
authors.forename: Hong-Qiang
authors.initials: HQ
authors.lastname: Shen
authors.forename: Yong-Min
authors.initials: YM
authors.lastname: Tang
authors.forename: Hua
authors.initials: H
authors.lastname: Song
authors.forename: Shu-Wen
authors.initials: SW
authors.lastname: Shi
authors.forename: Shi-Long
authors.initials: SL
authors.lastname: Yang
authors.forename: Wei-Qun
authors.initials: WQ
authors.lastname: Xu
authors.forename: Bai-Qing
authors.initials: BQ
authors.lastname: Qian
mesh_terms: D000293:Adolescent; D000328:Adult; D039481:CD11b Antigen / Q000032:analysis*; D002648:Child; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000235:genetics / Q000276:immunology; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D011379:Prognosis; D019009:Proto-Oncogene Proteins c-kit / Q000032:analysis*
chemical_list: D039481:CD11b Antigen; D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D019009:Proto-Oncogene Proteins c-kit